Use this exit readiness checklist to identify gaps, boost your EBITDA multiple, and position your practice for a premium acquisition by a PE-backed platform or independent physician buyer.
Selling a dermatology practice is one of the most significant financial events of a physician's career — and the difference between a 4x and 7x EBITDA multiple often comes down to how well you've prepared. Private equity-backed dermatology roll-ups and SBA-financed physician buyers are actively acquiring practices in the $1M–$5M revenue range, but they apply rigorous due diligence standards. Buyers scrutinize your payer mix, physician dependency risk, malpractice history, cosmetic revenue documentation, and lease terms before making an offer. This checklist walks you through every dimension of exit readiness — from financial presentation to clinical compliance — across a 12–24 month preparation timeline. Start early, address your value killers proactively, and you'll be positioned to command the highest possible multiple when the right buyer comes to the table.
Get Your Free Dermatology Practice Exit ScoreCompile 3 Years of Reviewed or Audited Financial Statements
Engage a healthcare-experienced CPA to prepare reviewed or audited financials for the past three fiscal years. Ensure all personal expenses — personal vehicle costs, family salaries, owner life insurance premiums, and discretionary travel — are clearly identified and added back to EBITDA. Buyers and SBA lenders will reconstruct your earnings based on these documents, so clean financials are non-negotiable.
Separate and Document Cosmetic vs. Medical Revenue Streams
Segment all revenue by category — medical dermatology (insurance-reimbursed), surgical procedures, and cash-pay cosmetic services (Botox, fillers, laser treatments, chemical peels). Provide gross revenue, cost of goods, and net margin for each segment. PE buyers assign premium valuations to cosmetic revenue due to its high margins and immunity to insurance reimbursement risk.
Audit Revenue Cycle Management and Collections Performance
Pull your collections rate, days in accounts receivable, denial rate by payer, and write-off history for the past 36 months. A collections rate below 90% or AR days exceeding 45 signals billing inefficiency that buyers will use to negotiate price down. If you use a third-party billing company, request a formal performance report and address any chronic denial patterns before going to market.
Normalize Owner Compensation to Market Rate
If you are the primary dermatologist, document what a replacement physician would cost at fair market value — typically $300K–$450K annually for a board-certified dermatologist. Buyers calculate post-acquisition EBITDA after replacing your compensation with a market-rate physician salary. Understanding this number prevents surprises during LOI negotiation and helps you present a realistic normalized EBITDA.
Build a 3-Year Financial Trend Narrative
Prepare a concise written explanation of revenue trends, including any pandemic-era dips, equipment investments that temporarily reduced margins, or cosmetic service line expansions driving recent growth. Buyers want to understand trajectory. A practice showing 8–12% annual revenue growth commands significantly more interest than a flat-revenue practice, even at similar EBITDA levels.
Review and Update All Physician and Mid-Level Provider Employment Agreements
Ensure every dermatologist, PA, and NP on staff has a current, signed employment agreement that includes defined compensation terms, non-solicitation clauses, and non-compete provisions appropriate for your state. Buyers — especially PE platforms — will not close without enforceable employment agreements in place for all clinical providers. Agreements that are expired, oral, or ambiguously written are immediate red flags.
Assess and Reduce Key-Person Dependency on the Founding Physician
If you personally generate 80%+ of practice revenue, buyers will price in significant key-person risk. Begin transitioning patient relationships to associate dermatologists or trained PAs and NPs. Cross-train your clinical team to handle medical dermatology volume independently. Even a 12-month track record of distributed revenue generation materially de-risks the acquisition in a buyer's eyes.
Clarify Post-Close Employment Expectations for Yourself
Determine how long you are willing to stay on post-acquisition — most buyers require a 12–24 month transition period, and PE platforms may require an earnout tied to EBITDA performance. Decide whether you want a clean break, a part-time clinical role, or a longer transition. Having clarity on your own post-close availability before entering negotiations prevents surprises that kill deals at the LOI stage.
Evaluate Non-Compete Enforceability in Your State
Non-compete enforceability varies dramatically by state — California effectively bans them, while states like Texas and Florida enforce them with specific geographic and duration requirements. Have a healthcare M&A attorney review all existing non-competes and assess whether they would survive a legal challenge. If you are the selling physician, understand what post-close restrictions you will personally be subject to and ensure they are reasonable given your intended plans.
Compile and Audit All Payer Contracts and Reimbursement Rates
Gather every active payer contract — commercial insurers, Medicare, Medicaid, and any managed care agreements — and document current reimbursement rates for your top 20 CPT codes. Identify any contracts approaching expiration or with unfavorable rate terms. Buyers performing due diligence will request this information within the first 30 days, and disorganized or incomplete contract files extend timelines and signal operational weakness.
Verify All State Licensure, DEA Registrations, and Medicare/Medicaid Enrollments Are Current
Confirm that every physician, PA, and NP has a current, unrestricted state medical license, active DEA registration if applicable, and up-to-date Medicare and Medicaid provider enrollment. Gaps in any of these during due diligence trigger compliance concerns that can delay or derail closings. Request a compliance audit from your healthcare attorney or practice administrator 12–18 months before going to market.
Understand and Address Corporate Practice of Medicine Compliance in Your State
Most states prohibit non-physicians from directly owning a medical practice, which means PE buyers must use a Management Services Organization (MSO) structure to acquire your practice. Engage a healthcare M&A attorney familiar with your state's corporate practice of medicine (CPOM) laws to understand how this affects deal structure. Some states, like California, have strict CPOM rules; others are more permissive. Getting ahead of this issue prevents structural surprises during LOI negotiations.
Review HIPAA Compliance and Patient Data Security Practices
Ensure your practice has completed a formal HIPAA Security Risk Assessment within the last 12 months, has a current Business Associate Agreement with all vendors handling PHI, and maintains a documented breach response policy. PE buyers and their legal counsel will request evidence of HIPAA compliance during due diligence. Gaps expose you to indemnification claims post-close.
Audit Full Malpractice Claims History and Obtain a Claims Summary Report
Request a formal claims history report from your malpractice insurer covering all claims, lawsuits, and settlements for the past 7–10 years. Buyers will conduct a National Practitioner Data Bank (NPDB) query on all physicians. Any pending, open, or unresolved claims must be disclosed and addressed proactively. Undisclosed malpractice history discovered during due diligence is a deal-killer.
Clarify Occurrence vs. Claims-Made Malpractice Coverage and Tail Insurance Plan
If your malpractice policy is a claims-made policy (most common), you will need to purchase a tail insurance policy upon sale to cover claims arising from incidents that occurred before the sale but are reported after. Occurrence-based policies do not require tail coverage. Clarify your current policy type, obtain a tail coverage quote, and factor the cost — typically 1.5x–2x your annual premium — into your net proceeds calculation. Buyers expect sellers to handle tail coverage at their own expense.
Confirm No Open State Medical Board Actions or Investigations
Verify that no physicians, PAs, or NPs in the practice are subject to any open state medical board investigations, license restrictions, or consent orders. Board actions are publicly discoverable and will surface immediately during buyer due diligence. Any such issues must be resolved or disclosed upfront — attempting to conceal them exposes you to post-close legal liability and deal rescission.
Review All Business Contracts for Assignment Provisions
Identify every material vendor contract, equipment lease, and service agreement that the practice is party to — including your EMR/practice management software agreement, equipment finance leases, and any outsourced billing contracts. Determine whether these contracts require third-party consent for assignment upon sale. Flag any contracts with change-of-control provisions that could trigger termination or renegotiation.
Confirm Lease Terms, Renewal Options, and Landlord Assignment Consent
Review your office lease and confirm the remaining lease term, renewal option periods, and any landlord consent requirements for assignment upon sale. Buyers — especially PE platforms — require a minimum of 3–5 years of remaining lease term post-close. If your lease expires within 12 months, negotiate a renewal before going to market. Verify whether your lease contains a change-of-control clause requiring landlord approval for the transaction.
Assess Dermatology Equipment Condition, Age, and Ownership Status
Inventory all major clinical equipment — laser platforms, phototherapy units, Mohs surgery equipment, excimer lasers, and aesthetic devices — and document age, service history, and ownership status (owned outright vs. leased or financed). Outdated or poorly maintained equipment will trigger buyer requests for price credits. Equipment that is leased must be disclosed and the lease terms reviewed for assignment provisions.
Evaluate EMR and Practice Management System Modernization
Assess whether your current EMR system — such as Modernizing Medicine (EMA), Nextech, or Athenahealth — is up to date, properly licensed, and capable of integration with common PE platform systems. Legacy or outdated systems signal operational risk and integration cost to buyers. If a system upgrade is feasible within your budget and timeline, prioritize EMR platforms commonly used by dermatology roll-up buyers to reduce post-close integration friction.
Document Patient Volume, Appointment Mix, and New Patient Acquisition Trends
Prepare a 24-month report of total patient visits, broken down by medical dermatology, surgical, and cosmetic appointments. Include new patient volume, return visit rates, no-show rates, and average revenue per visit by service type. Buyers evaluate these metrics to assess practice health, scheduling efficiency, and the sustainability of patient volume post-acquisition.
Build and Document an Online Reputation Strategy
Review your Google, Healthgrades, RealSelf, and Yelp profiles. A practice with 4.5+ star ratings across multiple platforms with 100+ reviews signals strong patient satisfaction and community brand value — both increasingly important to PE buyers evaluating patient acquisition costs. If your online presence is thin or damaged, implement a systematic patient review outreach program 9–12 months before going to market.
Engage a Healthcare M&A Advisor or Dermatology Practice Broker
Retain an M&A advisor or business broker with specific experience in healthcare and dermatology practice transactions. A generalist broker unfamiliar with MSO structures, CPOM laws, or PE roll-up buyer criteria will undervalue your practice and introduce legal risk during deal structuring. Your advisor should have relationships with active dermatology PE platforms and physician buyer networks, and should be compensated on a success-fee basis aligned with maximizing your sale price.
Prepare a Confidential Information Memorandum (CIM) Specific to Dermatology
Work with your advisor to prepare a professional CIM that tells the story of your practice — its history, clinical team, payer mix, cosmetic revenue mix, patient demographics, facility, and growth opportunities. The CIM should include normalized financials, revenue segmentation, and a clear explanation of why this practice is an attractive acquisition target. PE buyers and their investment teams evaluate dozens of practices and will quickly pass on poorly documented opportunities.
Establish a Realistic Valuation Expectation Based on Current Market Multiples
Dermatology practices currently trade at 4x–7x EBITDA depending on size, cosmetic revenue mix, physician depth, payer mix, and market geography. Work with your advisor to establish a realistic asking price range before engaging buyers. Overpriced practices that sit on the market for 6+ months develop stigma that reduces final sale prices. Underpriced practices leave real money on the table.
See What Your Dermatology Practice Business Is Worth
Free exit score, valuation range, and personalized action plan — 5 minutes.
Most dermatology practice sales take 12–18 months from initial preparation to close, though the active marketing and deal process itself typically runs 6–9 months. The preparation phase — cleaning up financials, updating employment agreements, auditing payer contracts, and addressing compliance issues — is what takes the most time. Practices that begin preparing 18–24 months before their target exit date consistently achieve faster closings and higher valuations than those that rush to market unprepared.
Dermatology practices in the lower middle market currently trade at 4x–7x adjusted EBITDA. Where you land in that range depends primarily on your cosmetic revenue mix, physician depth (2+ providers vs. solo), payer mix quality, revenue growth trend, and how clean your financials and compliance records are. A solo physician practice with heavy Medicare dependence and no succession plan may struggle to exceed 4x, while a multi-provider practice with 35% cosmetic revenue and clean documentation can command 6x–7x from a PE roll-up buyer.
Yes — full disclosure of all malpractice claims, settlements, and open investigations is both legally required and strategically essential. Buyers conduct National Practitioner Data Bank queries on all physicians and will independently discover any claims history. Attempting to conceal or minimize claims will destroy buyer trust and expose you to post-close fraud claims and indemnification liability. The better strategy is to obtain a formal claims summary from your insurer, understand the nature of each claim, and prepare a clear narrative that contextualizes any historical incidents.
An MSO (Management Services Organization) structure is the most common acquisition framework used when private equity buyers or non-physician investors acquire a medical practice. Because most states prohibit direct ownership of a medical practice by non-physicians under corporate practice of medicine (CPOM) laws, the buyer creates a separate management company that contracts with a physician-owned professional corporation to provide administrative and operational services. In practice, the PE buyer owns the MSO and controls the economics of the business, while the physician entity maintains nominal ownership of the clinical operations. Understanding this structure — and having a healthcare M&A attorney review how your state's CPOM laws apply — is essential before you enter any acquisition negotiation.
Most buyers — especially PE roll-up platforms — intend to retain existing clinical and administrative staff because replacing trained dermatology support staff is expensive and disruptive. However, staff retention is not contractually guaranteed in most deals, and PE buyers may restructure administrative functions to align with their platform's systems. As a seller, you can negotiate specific staff retention provisions into the purchase agreement for key employees, particularly clinical staff whose departure could affect patient care continuity or trigger payer contract issues. Communicate clearly with your team throughout the process to reduce voluntary attrition before and after close.
Cosmetic revenue — Botox, dermal fillers, laser treatments, chemical peels, and body contouring — is highly valued by buyers because it is cash-pay (no insurance reimbursement risk), high-margin (60–80% gross margin), and growing faster than medical dermatology. PE buyers in particular assign premium valuations to practices with a strong cosmetic revenue mix because it reduces payer contract dependency and creates upside through service line expansion. However, buyers will scrutinize cosmetic revenue closely to ensure it is tied to clinical relationships and not entirely dependent on the personal brand or social media following of the selling physician. Documenting the operational systems behind your cosmetic revenue — staff training, marketing channels, treatment protocols — strengthens this revenue stream in a buyer's eyes.
Tail insurance — formally called an Extended Reporting Period endorsement — covers malpractice claims that are reported after the sale but arise from incidents that occurred while you were practicing before the sale. It is required when a physician carries a claims-made malpractice policy (as opposed to an occurrence policy). In virtually all dermatology practice transactions, the seller is responsible for purchasing their own tail coverage, and the cost — typically 1.5x–2x your annual premium — should be factored into your net proceeds calculation before agreeing to a sale price. Tail coverage for a single dermatologist can range from $15,000 to $50,000 depending on your specialty focus, claims history, and years of practice.
In an asset purchase — the most common structure for dermatology practice acquisitions — your existing payer contracts typically do not automatically transfer to the buyer. The new practice entity must re-credential with each payer and negotiate new contracts, a process that can take 60–180 days depending on the payer. This gap can create temporary revenue disruption post-close. Some buyers negotiate interim billing arrangements using the seller's provider numbers (with appropriate legal guidance), and some payers allow contract assignment. Your healthcare M&A attorney should address payer contract continuity in the purchase agreement, and you should disclose payer contract terms — particularly any favorable rates negotiated over many years — as part of your CIM.
More Dermatology Practice Seller Guides
More Exit Checklists
Get your Dermatology Practice exit score, estimated valuation, and a step-by-step action plan — free, in 5 minutes.
Start Your Free Exit AssessmentFree forever · No broker needed · Takes 5 minutes
For Buyers
For Sellers